|Place your mouse over each cart item to see full description.
MediSave.ca is Moving!
MediSave is merging with our flagship website CanadaPharmacyOnline.com.
CPO provides the same prices for products from the same suppliers, the same outstanding customer service, but cheaper shipping for customers.
If you are an existing customer, your account will be transferred to CPO.
You can do the transfer your self by clicking Transfer to CPO
If you have questions, please call Medisave customer service at 1.877.888.3784. A customer service repesentitive will answer your questions and do the transfer for you.
Not an existing customer? It is a good oppertunity to open your account with us by clicking CanadaPharmacyOnline.com
Chemical Name: Aripiprazole
Abilify (Aripiperazole) is an atypical antipsychotic. Abilify (aripiprazole) is a partial agonist that uniquely modulates dopamine activity. The typical starting dose of Abilify (Aripiperazole) is 15mg taken once daily. Abilify (aripiprazole) is available in dosages ranging from 10mg to 30mg. No titration is required to reach an effective dose and Abilify can be taken without regards to meals.
Abilify (aripiprazole) acts as a functional antagonist with activity at D2 receptors in a hyperdopaminergic environment and as a functional agonist with activity at D2 receptors in a hypodopaminergic environment. In addition, Abilify (aripiprazole) has serotonin antagonist activity at 5-HT2A receptors and partial agonist activity at 5-HT1A receptors. Abilify (aripiprazole) also has moderate affinity for alpha1-adrenergic and histamine (H1) receptors and has no appreciable affinity for cholinergic muscarinic receptors.
The mechanism of action of Abilify (aripiprazole), as with other drugs having efficacy in schizophrenia, is unknown. However, it has been proposed that the efficacy of Abilify (aripiprazole) is mediated through a combination of partial agonist activity at dopamine D2 receptors and serotonin 5HT1A receptors, and antagonist activity at serotonin 5HT2A receptors. Partial agonism refers to the ability to both block a receptor if it is overstimulated and to stimulate a receptor when activity is needed.
Abilify Side Effects:
Abilify side effects include weight gain (1kg over 1 year), sedation, extra pyramidal side effects, and hyperporlactinemia. As with all antipsychotic medications, a rare condition referred to as neuroleptic malignant syndrome (NMS) has been reported. As with all antipsychotic medications, prescribing should be consistent with the need to minimize the risk of tardive dyskinesia (TD).
Abilify side effects may be associated with orthostatic hypotension and should be used with caution in patients with known cardiovascular disease, cerebrovascular disease, or conditions which would predispose them to hypotension.
As with other antipsychotic drugs, Abilify should be used with caution in patients with a history of seizures or with conditions that lower the seizure threshold. Seizures occurred in 0.1% of patients treated with Abilify in placebo-controlled trials.
There is no body of evidence available from controlled trials to answer the question of how long a patient treated with aripiprazole should remain on it. It is generally agreed, however, that pharmacological treatment for episodes of acute schizophrenia should continue for up to 6 months or longer. Patients should be periodically reassessed to determine the need for maintenance treatment.
No dosage adjustment for Abilify is required for: Patients with renal or hepatic impairment, Age, gender, race, or smoking status. Abilify is unlikely to affect the plasma levels of other drugs metabolized by P450 enzymes. Dosage adjustment of Abilify is recommended with: Potent inducers of CYP3A4, such as carbamazepine, Potent inhibitors of CYP3A4, such as ketoconazole, or of CYP2D6, such as quinidine, fluoxetine, and paroxetine.
Abilify is currently available in Canada through the Special Access Program with Health Canada. Canadian patients should speak to there doctor to apply for the program. For American customers, rest assured that Abilify should be released for sale within the next 6 to 12 months at a cost much less than on the market in the United States. You will be able to purchase Abilify from Medisave.ca Canadian Pharmacy before it becomes available at any other Canadian Pharmacy.
The generic alternative is not manufactured by the company that makes the brand product.
All prices are in US dollars.ollars.
The content on this page has been supplied to MediSave.ca by an independent third party contracted to provide information for our website. MediSave.ca relies on these third parties to create and maintain this information and cannot guarantee the medical efficacy, accuracy or reliability of the information that has been provided to us. If you require any advice or information about the drugs on this page, a medical condition or treatment advice, you should always speak to a health professional. Please note that not all products, including any referenced in this page, are shipped by our affiliated Canadian Pharmacy. We affiliate with other dispensaries that ship product to our customers from the following jurisdictions: Canada, Singapore, New Zealand, Turkey, Mauritius, India, and United Kingdom. The items in your order maybe shipped from any of the above jurisdictions. The products are sourced from various countries as well as those listed above. Rest assured, we only affiliate with our authorized dispensaries that procure product through reliable sources.
Back to Main Drug Information Page